GPCR STRUCTURE THERAPEUTICS

Structure Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences

Structure Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences

SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in two upcoming healthcare conferences in September.

Cantor Global Healthcare Conference
 Format:Fireside chat and 1x1 meetings
 Date/time:Wednesday, September 3 at 3:55 p.m. ET
 Location:New York, NY
   


Morgan Stanley 23rd Annual Global Healthcare Conference

 Format:Fireside chat and 1x1 meetings
 Date/time:Wednesday, September 10 at 10:45 a.m. ET
 Location:New York, NY
   

The live and archived webcasts will be accessible from the company’s website at and replays will be available for 90 days.

About Structure Therapeutics 

Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. For additional information, please visit .

Investors:

Danielle Keatley

Structure Therapeutics Inc.

Media:

Dan Budwick

1AB



EN
02/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on STRUCTURE THERAPEUTICS

 PRESS RELEASE

Structure Therapeutics to Participate in Two Upcoming Healthcare Inves...

Structure Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in two upcoming healthcare conferences in September. Cantor Global Healthcare Conference Format:Fireside chat and 1x1 meetings Date/time:Wednesday, September 3 at 3:55 p.m. ET Location:New York, NY   Morgan Stanley 2...

 PRESS RELEASE

Structure Therapeutics Reports Second Quarter 2025 Financial Results a...

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts Aleniglipron clinical development program expanded to optimize competitive positioning and Phase 3 program Oral small molecule amylin receptor agonist (ACCG-2671) Phase 1 initiation anticipated by year-end 2025 Strong financial position with cash, cash equivalents and short-term investments of $786.5 million as of June 30, 2025 expected to fund projected ...

 PRESS RELEASE

Structure Therapeutics Announces Two Late-Breaking Poster Presentation...

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671 SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, being held from June 20-23 in Chicag...

 PRESS RELEASE

Structure Therapeutics to Participate in Multiple Upcoming Healthcare ...

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences SAN FRANCISCO, May 29, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences in June. Jefferies Global Healthcare Conference Format: Fireside chat and 1x1 meetingsDate/time: Thursday, June 5 at 8:10 a.m. ETLocation: New York, NY Goldman Sachs Global Healthcare Conferen...

 PRESS RELEASE

Structure Therapeutics Reports First Quarter 2025 Financial Results an...

Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights Topline data from oral small molecule aleniglipron (GSBR-1290) Phase 2b ACCESS and ACCESS II studies anticipated by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Phase 1 initiation anticipated by year-end 2025; New preclinical data to be presented at American Diabetes Association (ADA) 85th Scientific Sessions in June 2025 Strong financial position with cash, cash equivalents and short-term investments of $836.9 million SAN FRANCISCO, May 08, 2025 (GLOBE NEWSWI...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch